Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 191

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution

Open access
Rizzieri, David A., Koh, Liang Piu, Long, Gwynn D., Gasparetto, Cristina, Sullivan, Keith M., Horwitz, Mitchell, Chute, John, Smith, Clayton, Gong, Jerald Z., Lagoo, Anand, Niedzwiecki, Donna, Dowell, Jeannette M., Waters-Pick, Barbara, Liu, CongXiao, Marshall, Dawn, Vredenburgh, James J., Gockerman, Jon, Decastro, Carlos, Moore, Joseph, Chao, Nelson J.·2007·Journal of Clinical Oncology

Abstract

Purpose: Allogeneic transplantation is typically limited to younger patients having a matched donor. To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related donor with one fully mismatched HLA haplotype. Patients and Methods: Fludarabine, cyclophosphamide, and alemtuzumab were used as the preparatory regimen. Additional graft-versus-host disease (GVHD) prophylaxis included mycophenolate with or without cyclosporine. Patients with persistence of disease had a donor lymphocyte boost planned. Toxicities, engraftment, response, survival, and immune recovery are reported. Results: Forty-nine patients with hematologic malignancies or marrow failure and no other available donors were enrolled. Ninety-four percent of patients had successful engraftment, and 8% had secondary graft failure. The treatment-related mortality rate was 10.2%, and 8% of patients had severe GVHD. Encouraging evidence of quantitative lymphocyte recovery through expansion of transplanted T cells was noted by 3 to 6 months. Seventy-five percent of patients attained a complete remission, and 1-year survival rate was 31% (95% CI, 18% to 44%). A standard-risk group of 19 patients with aplasia or in remission at transplantation demonstrated a 63% 1-year survival rate (95% CI, 38% to 80%) and 2.9-year median overall survival time (95% CI, 6.2 to 48 months). Conclusion: Nonmyeloablative therapy using haploidentical family member donors is feasible because the main obstacles of GVHD and graft rejection are manageable, allowing readily available stem-cell donors to be found for nearly all patients. Further qualitative and quantitative improvement in immune recovery is needed to address the high rate of relapse and risk of severe infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.07.0953

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 191

Metadata

Authors
Rizzieri, D. A., Koh, L. P., Long, G. D., Gasparetto, C., Sullivan, K. M., Horwitz, M., Chute, J., Smith, C., Gong, J. Z., Lagoo, A., Niedzwiecki, D., Dowell, J. M., Waters-Pick, B., Liu, C., Marshall, D., Vredenburgh, J. J., Gockerman, J., Decastro, C., Moore, J., & Chao, N. J.
Venue
Journal of Clinical Oncology
Published
2007-02-09
Volume
25
Issue
6
Pages
690-697
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2111951140
Cited by
191
References
1
FWCI
12.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution. https://app.cochat.ai/papers/10.1200/jco.2006.07.0953
The paper
Rizzieri, D. A., Koh, L. P., Long, G. D., Gasparetto, C., Sullivan, K. M., Horwitz, M., Chute, J., Smith, C., Gong, J. Z., Lagoo, A., Niedzwiecki, D., Dowell, J. M., Waters-Pick, B., Liu, C., Marshall, D., Vredenburgh, J. J., Gockerman, J., Decastro, C., Moore, J., & Chao, N. J. (2007). Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.07.0953

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.